Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Mar 13;30(5):797-801.
doi: 10.1097/QAD.0000000000000985.

Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV

Saskia Den Boon  1 , Alberto Matteelli, Nathan Ford, Haileyesus Getahun
Affiliations
Meta-Analysis

Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV

Saskia Den Boon et al. AIDS. .

Abstract

Objective: This systematic review was carried out to determine the effectiveness of continuous isoniazid (given for at least 36 months) for the treatment of latent tuberculosis infection (LTBI) in people living with HIV (PLHIV).

Methods: Six databases and HIV and tuberculosis (TB) conference abstract books were searched for randomized controlled trials that compared the effectiveness of continuous isoniazid with 6 months of isoniazid. Outcomes of interest were TB incidence, mortality, adverse events and risk of drug resistance. Data were pooled using fixed-effects meta-analysis.

Results: Three studies were included, from Botswana, South Africa and India. The risk of active TB was 38% lower among patients receiving continuous isoniazid compared with isoniazid regimen for 6 months [relative risk (RR) 0.62, 95% confidence interval (CI): 0.42-0.89; I = 0%], and 49% lower for those with a positive tuberculin skin test (TST) (RR 0.51, 95% CI: 0.30-0.86; I = 7%). Similarly, individuals with positive TST had a 50% lower chance of death (RR 0.50, 95% CI: 0.27-0.91; I = 3%). Two studies found no evidence of an increase in adverse events in the continuous isoniazid group, whereas a third study, that used a different definition for adverse events, found strong evidence of increase. There was no evidence of increased drug resistance when continuous isoniazid was given.

Conclusion: For PLHIV in settings with high TB and HIV prevalence and transmission, continuous isoniazid for at least 36 months is beneficial and probably outweighs the risk of increased adverse events compared with an isoniazid regimen for 6 months.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1. Study selection process.
Fig. 2
Fig. 2
(a) Forest plot showing the results of the fixed-effects meta-analysis for active TB (confirmed, probable and possible TB), overall results and stratified according to TST status. (b) Forest plot showing the results of the fixed-effects meta-analysis for death, overall results and stratified according to TST status.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) Guidelines for intensified case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland: WHO; 2011.
    1. Tuberculosis preventive therapy in HIV-infected individuals. A Joint Statement of the WHO and IUATLD. Wkly Epidemiol Rec. 1993;68:361–364. - PubMed
    1. Getahun H, Matteelli A, Chaisson RE, Raviglioni M. Latent Mycobacterium tuberculosis Infection. N Engl J Med. 2015;372:2127–2135. - PubMed
    1. Houben RM, Sumner T, Grant AD, White RG. Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings. Proc Natl Acad Sci USA. 2014;111:5325–5330. - PMC - PubMed
    1. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse and reinfection of tuberculosis after cure: a cohort in South African mineworkers. Lancet. 2001;358:1687–1693. - PubMed